Literature DB >> 16135969

Olprinone reduces ischemia/reperfusion-induced acute renal injury in rats through enhancement of cAMP.

Akio Mizutani1, Kazunori Murakami, Kenji Okajima, Shin-Ichiro Kira, Sachiko Mizutani, Kyosuke Kudo, Junji Takatani, Koji Goto, Seiji Hattori, Takayuki Noguchi.   

Abstract

Activated leukocytes are implicated in development of ischemia/reperfusion (I/R)-induced organ injuries. Phosphodiesterase 3 inhibitors have anti-inflammatory effects by preventing cyclic adenosine monophosphate (cAMP) degradation. We examined the effects of olprinone, a specific phosphodiesterase 3 inhibitor, on I/R-induced acute renal injury model in rats. Forty-five minute renal I/R was induced in uni-nephrectomized rats. Rats were divided into a vehicle group, an olprinone group, and a dibutyril (DB) cAMP group. Olprinone (0.2 microg/kg/minute) infusion began 30 min after reperfusion and continued for 3 h. DBcAMP (5 mg/kg), a stable analog of cAMP, was intraperitoneally administered 5 min after reperfusion to clarify the effect of cAMP in our model. Olprinone reduced the I/R-induced increases in serum levels of blood urea nitrogen and creatinine, and improved histological changes, including acute tubular necrosis in the outer medulla. Hemodynamic status was not affected by olprinone. I/R-induced a decrease in renal tissue blood flow, an increase in renal vascular permeability, and an enhancement of leukocyte activation, reflected by renal tissue levels of myeloperoxidase activity, and the tissue levels of cytokine-induced neutrophil chemoattractant (an equivalent of human interleukin 8) and tumor necrosis factor-alpha were all significantly decreased by olprinone. Olprinone also increased the renal tissue and plasma levels of cAMP in rats subjected to renal I/R. DBcAMP showed similar effects. Our results indicated that olprinone reduced the I/R-induced acute renal injury, probably by inhibiting leukocyte activation. The effects of olprinone could be explained through its action on cAMP levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135969     DOI: 10.1097/01.shk.0000175555.95676.34

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  6 in total

1.  Epac-Rap signaling reduces cellular stress and ischemia-induced kidney failure.

Authors:  Geurt Stokman; Yu Qin; Hans-Gottfried Genieser; Frank Schwede; Emile de Heer; Johannes L Bos; Ingeborg M Bajema; Bob van de Water; Leo S Price
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

2.  Olprinone attenuates the development of ischemia/reperfusion injury of the gut.

Authors:  Concetta Crisafulli; Emanuela Mazzon; Maria Galuppo; Irene Paterniti; Rocco Caminiti; Salvatore Cuzzocrea
Journal:  Intensive Care Med       Date:  2010-03-27       Impact factor: 17.440

3.  The effects of tadalafil on renal ischemia reperfusion injury: an experimental study.

Authors:  Feyzul Gasanov; Berna Aytac; Hakan Vuruskan
Journal:  Bosn J Basic Med Sci       Date:  2011-08       Impact factor: 3.363

4.  Reversal of oxidant-mediated biochemical injury and prompt functional recovery after prolonged single-dose crystalloid cardioplegic arrest in the infantile piglet heart by terminal warm-blood cardioplegia supplemented with phosphodiesterase III inhibitor.

Authors:  Katsushi Kinouchi; Kiyozo Morita; Yoshihiro Ko; Ryuichi Nagahori; Gen Shinohara; Takayuki Abe; Kazuhiro Hashimoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-02-12

5.  Olprinone attenuates the acute inflammatory response and apoptosis after spinal cord trauma in mice.

Authors:  Emanuela Esposito; Emanuela Mazzon; Irene Paterniti; Daniela Impellizzeri; Placido Bramanti; Salvatore Cuzzocrea
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

6.  The role of phosphodiesterase 3 in endotoxin-induced acute kidney injury.

Authors:  Won-Il Choi; Kun Young Kwon; Jeong Wook Seo; John Beagle; Deborah A Quinn; Charles A Hales
Journal:  BMC Infect Dis       Date:  2009-06-01       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.